Clinical trial
Cilostazol in Acute Ischemic Stroke Treatment (CAIST)
NCT00272454 · Korea Otsuka Pharmaceutical Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT00272454 |
|---|---|
| Title | Cilostazol in Acute Ischemic Stroke Treatment (CAIST) |
| Official title | The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke |
| Lead sponsor | Korea Otsuka Pharmaceutical Co., Ltd., Industry |
| Collaborators | Seoul National University Boramae Hospital Korea Otsuka International Asia Arab Co., Ltd. |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cerebral Infarction |
| Intervention type | Drug |
| Interventions | Cilostazol, Aspirin |
| Enrollment | 468 |
| Start date | Jan 1, 2006 |
| Completion | Sep 1, 2008 |
| First posted | Jan 6, 2006 |
| Last update posted | Dec 16, 2009 |
| Countries | South Korea |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: